Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA

Recruiting now · Phase 2

Conditions studied: MDS (Myelodysplastic Syndrome), Aplastic Anemia (AA)

In brief

This study is for adults aged 18-65 with myelodysplastic syndrome (MDS) or severe aplastic anemia (AA) who are scheduled to receive a donor stem cell transplant (allogeneic hematopoietic stem cell transplant). After the transplant, it is critical for the body to start making its own blood cells again. A common and serious problem is a delay in the recovery of platelets (the cells that help stop bleeding), which increases the risk of bleeding, infection, and death. This study aims to see if a new treatment can help platelets recover faster and more safely after transplant. We are comparing two drugs: Romiplostim: A long-acting injection given just once a week. rhTPO (Recombinant Human Thrombopoietin): A standard injection given every day. Both drugs are designed to help the body make more platelets. The main question is whether the once-weekly romiplostim works as well or better than the daily rhTPO, and if it is safe. About 66 patients will participate. By random chance (like flipping a coin), each participant will be assigned to receive either romiplostim or rhTPO. The treatment will start a few days after the transplant and continue until platelets recover to a safe level or for up to 8 weeks. Doctors will closely monitor all participants for 100 days to track platelet recovery, need for transfusions, side effects, and overall health.

Key facts

Study ID

NCT07400341

Run by

The First Affiliated Hospital of Soochow University

People needed

66

Starts

2026-01-31

Expected to finish

2028-12-31

Last updated by the study team

2026-04-15

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-65 years (inclusive).
• Diagnosis of Myelodysplastic Syndrome (MDS) per WHO criteria, or Severe/Very Severe Aplastic Anemia (SAA/VSAA) per Camitta criteria, and deemed eligible for allogeneic hematopoietic stem cell transplantation (allo-HSCT).
• Planned to receive allo-HSCT from a matched sibling, haploidentical, or unrelated donor (including cord blood).
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
• Persistent platelet count <20×10⁹/L with platelet transfusion dependence between post-transplant days +4 and +10. Transfusion dependence is defined as platelet count not doubling within 24-48 hours after transfusion or ongoing need for prophylactic transfusion.
• Adequate cardiac, hepatic, and renal function as required for transplantation, per investigator assessment.
• Voluntary participation with written informed consent obtained prior to any study-specific procedures.

You may not qualify if…

• Active, uncontrolled bacterial, fungal, or viral infection at the time of enrollment.
• History of arterial thrombosis, or venous thromboembolism within the past 6 months (unless cured or stable for over 6 months).
• Active transplant-associated thrombotic microangiopathy (TA-TMA).
• Pre-transplant bone marrow biopsy showing fibrosis grade ≥ MF-2 (according to WHO criteria).
• Known hypersensitivity to Romiplostim, recombinant human thrombopoietin (rhTPO), or any of their excipients.
• Pregnant or lactating women.
• Women of childbearing potential or men with partners of childbearing potential who are unwilling to use highly effective contraception during the study period and for at least 3 months after the last dose of study drug.
• Any other condition that, in the opinion of the investigator, would make the patient unsuitable for participation in the study.

Where it is running

• The First Affiliated Hospital of Soochow University, Department of Hematology — Suzhou, Jiangsu, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.